Cholangiocarcinoma News and Research

RSS

Study shows how treatment resistance develops in patients with bile duct cancer

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute shows how resistance to a promising targeted drug develops in patients with a rare, lethal cancer of the bile ducts called cholangiocarcinoma.

14 Jan 2020

Data results of NCI-MATCH trial in tumors with DNA mismatch repair deficiencies

Final results are published from an evaluation of 42 patients treated with the immune checkpoint inhibitor nivolumab in the large multi-arm precision medicine trial, NCI-Molecular Analysis for Therapy Choice (NCI-MATCH or EAY131).

20 Dec 2019

Deaths from liver cancer increased 3-fold over 20 years in England

Liver cancer is rapidly moving up the cancer killer ranks in England, according to a new study that is to be presented at the 201th NCRI Cancer Conference on November 2, 2019. Both the number of new cases and the mortality rate from hepatocellular carcinoma (HCC), have tripled, over the period from 1997 to 2016. HCC is the most common form of liver cancer. Moreover, a quarter of these cases occur among the least privileged fifth of society.

3 Nov 2019

Patients with biliary tract cancer have altered genetic architecture in immune system

Patients with biliary tract cancer have altered genetic architecture in some immune system receptors.

26 Jun 2019

Novel radiotracer can identify nearly 30 types of malignant tumors

A novel class of radiopharmaceuticals has proven effective in non-invasively identifying nearly 30 types of malignant tumors, according to research published in the June issue of The Journal of Nuclear Medicine.

10 Jun 2019

Unusually small antibodies could help CAR T-cell therapies to kill solid tumors

In 1989, two undergraduate students at the Free University of Brussels were asked to test frozen blood serum from camels, and stumbled on a previously unknown kind of antibody. I

12 Apr 2019

Incyte announces Phase 2 FIGHT-202 trial data in patients with cholangiocarcinoma

Incyte Corporation announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment.

22 Oct 2018

GW researcher receives grant to examine link between liver fluke infection and bile duct cancer

Liver fluke infection is a major public health problem affecting more than 10 million people in Southeast Asia, particularly in Thailand and Laos. Infection has been strongly linked to cholangiocarcinoma, or bile duct cancer, an uncommon but aggressive form of cancer.

5 Sep 2018

TGen scientists develop new quality-control assay to detect cancer from patient's blood sample

Imagine how much patients could benefit if you could discover the presence of cancer, and even how that cancer develops over time, with a simple blood test.

10 May 2018

Study offers new hope for patients with intrahepatic cholangiocarcinoma

Kandice Fogle, 43, had just moved to Houston when she began experiencing pain in her back and groin. After undergoing a CT scan, doctors found a large mass in her liver. A biopsy confirmed that she had intrahepatic cholangiocarcinoma, more commonly known as bile duct cancer.

11 Apr 2018

Investigating new cancer therapy candidates with live-cell imaging

There are two main things that we've worked on in the lab as regards to drug studies. One is identifying new combinations of drugs, and working on why a combination of drugs should work better than each alone.

From Sartorius 16 Oct 2017

Highly sensitive blood test holds potential for quickly tracking cancer growth and spread

Stanford University scientists have described a new type of test that can detect genetic mutations in minute amounts of DNA released from cancer cells into the blood.

14 Aug 2017

'Mismatch repair' genetic defects drive cancer patient's response to immunotherapy drugs

In an expanded, three-year clinical trial of 86 patients with colorectal and 11 other kinds of cancer that have so-called 'mismatch repair' genetic defects, scientists at Johns Hopkins Medicine and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have found that half of the patients respond to an immunotherapy drug called pembrolizumab.

9 Jun 2017

Genetic sequencing could help direct treatment for 72% of advanced cancer patients

A new analysis finds that nearly three-quarters of 500 patients with advanced cancer could be referred to a potential targeted treatment based on the results of a comprehensive analysis of their tumor's genetic landscape.

2 Jun 2017

Researchers identify novel gene critical to development of lung and pancreatic cancer

Researchers at the Center for Applied Medical Research of the University of Navarra have identified a critical gene, FOSL1, in the development of lung and pancreatic cancer.

22 Feb 2017

Regular aspirin use may help reduce risk of bile duct cancer

Regular use of aspirin was linked with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma, in a recent study. The findings, which are published in the journal Hepatology, indicate that additional research on the potential of aspirin for preventing bile duct cancer is warranted.

27 Apr 2016

Aspirin use linked with reduced risk of developing bile duct cancer

A team of current and former Mayo Clinic researchers has discovered that aspirin use is associated with a significantly reduced risk of developing bile duct cancer, also called cholangiocarcinoma. The results are published in Hepatology.

20 Apr 2016

Alternative splicing: a new approach to drug development? An interview with Lucy Donaldson

RNA is becoming an interesting drug target as it takes possible intervention back one step to the synthesis of a target protein, instead of trying to block or inhibit a process.

1 Feb 2016

CCF approved for Eugene Washington Engagement Award by PCORI to support upcoming conference

The Cholangiocarcinoma Foundation has been approved for a Eugene Washington Engagement Award by the Patient-Centered Outcomes Research Institute to support its 2016 Annual Conference on February 3-6 in Salt Lake City.

26 Jan 2016

Findings could offer doctors new method to diagnose pancreatic cancer earlier in patients

By collecting samples from the portal vein--which carries blood from the gastrointestinal tract, including from the pancreas, to the liver--physicians can learn far more about a patient's pancreatic cancer than by relying on peripheral blood from a more easily accessed vein in the arm.

23 Nov 2015